- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05522998
Efficacy and Safety of Ciprofol in Laparoscopic Sleeve Gastrectomy
Efficacy and Safety of Ciprofol for the Induction of General Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To evaluate the efficacy and safety of ciprofol for the induction of general anesthesia in obese patients undergoing laparoscopic sleeve gastrectomy. A randomized, parallel, propofol injection positive control study will be conducted to select obese patients who will undergo laparoscopic sleeve gastrectomy in the author's hospital. To evaluate the efficacy and safety, the following indexes will be recorded and compared between the two groups.
- The main observation index:(1) The rate of successful anesthesia induction
- Secondary observation indexex:(1) Time from initial administration of study drug to loss of consciousness; (2) Time from initial administration of study drug to disappearance of eyelash reflex; (3) Changes in bispectral index(BIS) values during anesthesia induction
- Safety evaluation indexes:(1) Adverse events; (2) Intubation response rate; (3) Vital signs; (4) Evaluation of injection pain
- Adverse events to be focused on:(1)The incidence of blood pressure reduction requiring treatment during anesthesia induction; (2) The incidence of respiratory depression
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Xiaowei Chi, M.D.
- Phone Number: +8613708085545
- Email: mzkchixiaowei@yeah.net
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610031
- Recruiting
- The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University
-
Contact:
- Xiaowei Chi, M.D.
- Phone Number: +862861318772
- Email: mzkchixiaowei@yeah.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 < age ≤ 65, regardless of gender;
- ASA is classified as grade I-III;
- BMI≥35kg/m2
- Obese patients who need laparoscopic sleeve gastrectomy under general anesthesia;
- The subjects voluntarily participated in the trial and signed the informed consent.
Exclusion Criteria:
- Contraindications to general anesthesia;
- Accompanied by infectious heart disease such as myocarditis or endocarditis, septicemia;
- Brain injury, possible intracranial hypertension, cerebral aneurysm, cerebrovascular accident history and central nervous system diseases: mental system diseases (schizophrenia, mania, insanity, etc.) and long-term history of taking psychotropic drugs, or other diseases that hinder the measurement of BIS value;
- Acute heart failure, unstable angina pectoris, myocardial infarction within 6 months before screening, resting ECG heart rate ≤ 50 beats / min, third degree atrioventricular block and other serious arrhythmias, serious heart valve disease, QTc: male ≥ 450ms, female ≥ 470ms;
- Abnormal liver and kidney function (ALT or AST ≥ 2.5 times the upper limit of normal value, TBIL ≥ 1.5 times the upper limit of normal value), abnormal renal function (bun or urea ≥ 1.5 times the upper limit of normal value, cr> the upper limit of normal value, or dialysis treatment within 28 days before operation), or obvious abnormal coagulation function (pt/ aptt/tt higher than the upper limit of normal value), anemia or thrombocytopenia (HB ≤ 90g/l, PLT ≤ 80 × 109/L)
- Those whose blood pressure was not satisfactorily controlled (SBP ≥ 160mmhg and / or DBP ≥ 100 mmHg in sitting position during screening period);
- SBP in sitting position during screening period ≤ 90mmHg;
- Diabetes subjects whose blood glucose was not satisfactorily controlled (fasting blood glucose ≥ 11.1mmol/l in the screening period and / or random blood glucose ≥ 13.6 mmol/l);
- Have a history of drug abuse and alcoholism within 2 years before the screening period. Alcoholism is defined as regular drinking for more than 14 times / week (once =150 ml wine or 360 ml beer or 45 ml spirits);
- The subjects who were judged to have difficulty in respiratory management were rated as grade IV by modified Mahalanobis score;
- Known or suspected allergy or contraindication to various components of the study drug or other benzodiazepines, opioids, propofol, muscle relaxants, etc;
- Pregnant or lactating women or subjects with birth plan within 6 months (including men);
- Those who participated in any clinical trial as subjects within 3 months before enrollment;
- Other circumstances determined by the researcher as unsuitable for inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ciprofol Group
Experimental drug: Ciprofol; Dosage form: injection; Specification: 20ml: 50mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 0.4-0.5mg/kg,
Administration for 30s (± 5S)
|
Ciprofol (0.4-0.5mg/kg) for anesthesia induction
Other Names:
|
Active Comparator: Propofol Group
Experimental drug: Propofol; Dosage form: injection; Specification: 20ml: 200mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 2-2.5mg/kg,
Administration for 30s (± 5S)
|
propofol(2-2.5mg/kg)
for anesthesia induction
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of successful anesthesia induction
Time Frame: Through study completion, an average of 1 year
|
The criteria for success are to meet the following two requirements at the same time: 1) successful induction (i.e.
improved investigator awake / sedation score (MOAA / S) ≤ 1) after the administration of the study drug (at most 2 additional times are allowed); 2) No alternative anesthetics were used.
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to LOC
Time Frame: During anesthesia induction, an average of 10 minutes
|
Time from initial administration of study drug to loss of consciousness
|
During anesthesia induction, an average of 10 minutes
|
Time to disappearance of eyelash reflex
Time Frame: During anesthesia induction, an average of 10 minutes
|
Time from initial administration of study drug to disappearance of eyelash reflex
|
During anesthesia induction, an average of 10 minutes
|
BIS
Time Frame: During anesthesia induction, an average of 10 minutes
|
Changes in bispectral index(BIS) values during anesthesia induction
|
During anesthesia induction, an average of 10 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiaowei Chi, M.D., Third People's Hospital of Chengdu, Southwest Jiaotong University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bariatric Surgery
-
Unidad Internacional de Cirugia Bariatrica y MetabolicaRecruitingGERD | Bariatric Surgery Candidate | Revisional Bariatric SurgeryVenezuela
-
Universidad de ZaragozaCentro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas... and other collaboratorsRecruitingBariatric Surgery | Bariatric Surgery and Whole Body Vibration TrainingSpain
-
Cairo UniversityBatterjee Medical College; Taif UniversityCompletedSurgery | Bariatric SurgeryEgypt, Saudi Arabia
-
University of Illinois at Urbana-ChampaignCarle Foundation HospitalRecruitingBariatric Surgery Candidate | Bariatric Surgical ProcedureUnited States
-
McMaster UniversityNot yet recruitingRobotic Surgery | Bariatric Surgery
-
Western Galilee Hospital-NahariyaCompletedBariatric Patients Undergoing Bariatric SurgeryIsrael
-
Unidad Internacional de Cirugia Bariatrica y MetabolicaRecruiting
-
The University of Texas Health Science Center,...Recruiting
-
Centre Hospitalier Intercommunal CreteilRecruitingBariatric SurgeryFrance
-
Yale-NUS CollegeCompleted
Clinical Trials on Ciprofol
-
Zhejiang Cancer HospitalRecruiting
-
The Second Affiliated Hospital of Hainan Medical...RecruitingAdverse Effects | Intubation, IntratrachealChina
-
RenJi HospitalRecruitingGastric Cancer | Intestinal Polyps | Gastric Ulcer | Intestinal CancerChina
-
Capital Medical UniversityRecruitingMechanical Ventilation | Sedation and AnalgesiaChina
-
Le YuRecruiting
-
Nanfang Hospital, Southern Medical UniversityRecruitingSedation | Propofol | Low Blood Pressure | Norepinephrine | CiprofolChina
-
Sichuan Provincial People's HospitalActive, not recruiting
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingElderly | Post Induction Hypotension
-
Shanghai Zhongshan HospitalNot yet recruitingEmergency Tracheal Intubation in Critically Ill Patients
-
RenJi HospitalBeijing Hospital; Second Hospital of Shanxi Medical University; Zhejiang Tumor... and other collaboratorsRecruitingGastric Cancer | Gastric Ulcer | Gastrointestinal PolypChina